Zanubrutinib is a second-generation BTK inhibitor, reported to have fewer off-target toxicities while maintaining comparable efficacy to previous BTK inhibitors. Here, the authors report the phase II CHESS trial evaluating frontline Zanubrutinib (second-generation BTK inhibitor) plus rituximab (anti-CD20) induction, followed by chemoimmunotherapy in patients with mantle cell lymphoma.
- Yuchen Zhang
- Man Nie
- Qingqing Cai
